KPV research spans keratinocyte stress models and targeted colon-delivery systems. The published effects are preclinical, and FDA states that it has not identified human exposure data for drug products containing KPV.
Evidence at a glance
- A 2025 study used HaCaT keratinocytes and a 3D skin model; 50 µg/mL KPV restored cell viability and reduced IL-1β after PM10 exposure.
- A 2010 mouse-colitis study reported comparable activity with nanoparticle-delivered KPV at a 12,000-fold lower concentration than free KPV.
- FDA’s 2026 safety-risk page states that it has not identified human exposure data for KPV drug products by any route.
Study record
The 2025 paper measured cell viability, IL-1β, reactive oxygen species, MAPK signaling, NF-κB and apoptosis-related proteins. “Human HaCaT cells” means a human-derived immortalized cell line; it does not mean participants received KPV.
Results in context
The 2010 study engineered approximately 400 nm nanoparticles and placed them in an alginate/chitosan hydrogel intended to release in the colon. Cell assays and a DSS mouse model showed reduced inflammatory and histologic parameters. The result belongs to that delivery system and cannot be assigned automatically to free KPV.
A 2026 FDA page identifies missing human exposure and safety information, including whether KPV could cause harm when administered. That official boundary should accompany any discussion of promising cell or animal findings.
What the evidence cannot establish
No controlled human efficacy study was identified for the modeled skin or colitis outcomes.
Nanoparticle and hydrogel performance is formulation-specific.
Cell viability and mouse histology are not clinical endpoints.
Sources & editorial method
This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, sample size, model/population limits and regulatory scope are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- KPV mitigates fine-dust-induced keratinocyte apoptosis and inflammationCell study. 2025. PMID 40073467.
- Drug-loaded nanoparticles targeted to the colon reduce colitis in miceLaroui H, et al. Gastroenterology. 2010. PMID 19909746.
- Certain Bulk Drug Substances That May Present Significant Safety RisksU.S. FDA. Current compounding safety-information page.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
